CNBC’s Jim Cramer has cast doubt on reports surrounding a potential $400 billion merger between pharmaceutical heavyweights AstraZeneca PLC (NASDAQ:AZN) and Bristol-Myers Squibb Co. (NYSE:BMY).
Wall Street Skepticism Meets Pharma Mega-Merger Rumors
Reacting to reports of the massive transaction, Cramer asked in a post on X if the ongoing talks were an “Astra-Zeneca fake out?” while asserting that “BMY needs help …” as market participants evaluate what could become one of the largest corporate consolidations in global healthcare history.
AstraZeneca and Bristol-Myers Squibb did not immediately respond to Benzinga’s request for comment.
Details of the $400 Billion Potential Combination
The market speculation follows a report by the Financial Times indicating that AstraZeneca and Bristol Myers Squibb have engaged in discussions for several months.
While these negotiations could soon result in a transaction structured around both cash and shares, FT sources noted that delays or an outright collapse remain distinct possibilities.
If finalized, the merger would combine AstraZeneca’s estimated $263 billion market capitalization with Bristol Myers Squibb’s $133 billion valuation, creating a mega-corporation valued near $400 billion.
The potential transaction would easily surpass AstraZeneca’s previous record acquisition—the $39 billion purchase of Alexion in 2021—and position AstraZeneca as the world’s fourth-largest drugmaker by market capitalization.
Market Impact, AI Expansion, and Regulatory Scrutiny
A successful merger would significantly expand AstraZeneca’s operational reach within the United States market, raising fresh concerns in the United Kingdom following AstraZeneca’s recent decision to elevate its New York stock listing.
However, any formal agreement faces steep regulatory hurdles ahead. Both pharmaceutical firms maintain extensive oncology divisions, with cancer therapies accounting for nearly half of AstraZeneca’s product revenue following a recent 6% revenue increase.
Meanwhile, Bristol Myers Squibb has focused on enhancing its drug discovery capabilities through strategic artificial intelligence partnerships, including a collaboration with Anthropic. As a result, their overlapping cancer research portfolios are widely expected to attract heavy antitrust scrutiny from regulators.
How Has BMY Performed In 2026?
BMY shares were up 21,08% year-to-date, up 13.36% over the last month, and higher by 50.80% over the year. It closed 0.69% higher at $65.31 per share on Friday, and it was up 6.34% in premarket on Monday.
Benzinga’s Edge Stock Rankings indicate that BMY maintains a strong price trend in the short, long anbd medium terms, with a good quality score.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock
Login to comment